Effect of Anrotinib Combined with Pemetrexed on JAK/STAT3 Signaling Pathway in Advanced Non-squamous Non-small-cell Lung Cancer
Objective To investigate effect of anrotinib combined with pemetrexed on janus kinase/signal transducer and activator of transcription(JAK-STAT)signaling pathway in advanced non-squamous non-small-cell lung cancer.Methods 82 patients with advanced non squamous non-small cell lung cancer were randomly divided into 2 groups.The control group(41 cases)was treated with pemetrexed after operation,while the experimental group(41 cases)was treated with anlotinib on this ba-sis.Then the expression levels of JAK and STAT3 were recorded,and the clinical outcomes and adverse reactions during chemo-therapy were compared between the 2 groups.Results After treatment,the expression levels of JAK and STAT3 were significantly decreased in both groups,and the expression in the experimental group was obvious lower than the control group(P＜0.05).Com-pared with the total effective rate of the control group[70.73％(29/41)],the total effective rate of the experimental group[95.12％(39/41)]was significantly higher(P＜0.05);There was no significant difference in the incidence of adverse reactions between the control group[34.14％(14/41)]and the experimental group[21.95％(9/41)](P＞0.05).Conclusion Appli-cation of anrotinib based on pemetrexed therapy in the treatment of advanced non-squamous non-small-cell lung cancer after sur-gery can effectively inhibit the JAK/STAT3 signaling pathway without increasing adverse reactions.
万方数据
维普
